Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
Authors
Keywords
-
Journal
Nature Communications
Volume 12, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-04-22
DOI
10.1038/s41467-021-22619-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pathway-specific genome editing of PI3K/mTOR tumor suppressor genes reveals that PTEN loss contributes to cetuximab resistance in head and neck cancer
- (2020) Hiroki Izumi et al. MOLECULAR CANCER THERAPEUTICS
- 4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer
- (2019) Zhiyong Wang et al. CANCER RESEARCH
- Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma
- (2019) Umamaheswar Duvvuri et al. CLINICAL CANCER RESEARCH
- Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
- (2019) Zhiyong Wang et al. Nature Communications
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
- (2018) Ranee Mehra et al. BRITISH JOURNAL OF CANCER
- Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer
- (2018) Toni M. Brand et al. CANCER RESEARCH
- Myeloid-derived suppressor cells coming of age
- (2018) Filippo Veglia et al. NATURE IMMUNOLOGY
- Assembly and activation of the Hippo signalome by FAT1 tumor suppressor
- (2018) Daniel Martin et al. Nature Communications
- A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).
- (2018) Julie E. Bauman et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Approval Summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer
- (2018) Lynn J. Howie et al. CLINICAL CANCER RESEARCH
- Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial
- (2018) Terry A. Day et al. CLINICAL CANCER RESEARCH
- Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
- (2018) Magnus T. Dillon et al. CLINICAL CANCER RESEARCH
- Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
- (2018) Ezra E W Cohen et al. LANCET
- Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation
- (2018) Nicole Michael Frazier et al. ONCOGENE
- ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
- (2017) Diego Alvarado et al. PLoS One
- QuPath: Open source software for digital pathology image analysis
- (2017) Peter Bankhead et al. Scientific Reports
- American Cancer Society Head and Neck Cancer Survivorship Care Guideline
- (2016) Ezra E. W. Cohen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV + Patients
- (2016) Toni M. Brand et al. CLINICAL CANCER RESEARCH
- HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
- (2016) Dongsheng Wang et al. CLINICAL CANCER RESEARCH
- A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response
- (2016) Z. Xiao et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)
- (2016) Jérôme Fayette et al. Frontiers in Oncology
- Immunology and Immunotherapy of Head and Neck Cancer
- (2015) Robert L. Ferris JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration
- (2015) Sangwon Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The head and neck cancer cell oncogenome: A platform for the development of precision molecular therapies
- (2015) Daniel Martin et al. Oncotarget
- Exploiting the Head and Neck Cancer Oncogenome: Widespread PI3K-mTOR Pathway Alterations and Novel Molecular Targets
- (2013) R. Iglesias-Bartolome et al. Cancer Discovery
- Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
- (2013) V. W. Y. Lui et al. Cancer Discovery
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas
- (2012) A. A. Molinolo et al. CLINICAL CANCER RESEARCH
- Comparative Analysis of Tumor-Infiltrating Lymphocytes in a Syngeneic Mouse Model of Oral Cancer
- (2012) Nancy P. Judd et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness
- (2011) N. P. Judd et al. CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Changes in Survival in Head and Neck Cancers in the Late 20th and Early 21st Century: A Period Analysis
- (2010) D. Pulte et al. ONCOLOGIST
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
- (2008) Jan B. Vermorken et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started